Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis
Troy Noordenbos, Nataliya Yeremenko, Ioana Gofita, et al.
Arthritis & Rheumatism (2011) Vol. 64, Iss. 1, pp. 99-109
Closed Access | Times Cited: 261

Showing 1-25 of 261 citing articles:

Targeting IL-17 and TH17 cells in chronic inflammation
Pierre Miossec, Jay K. Kolls
Nature Reviews Drug Discovery (2012) Vol. 11, Iss. 10, pp. 763-776
Closed Access | Times Cited: 1252
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, J. Braun, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 26, pp. 2534-2548
Open Access | Times Cited: 903
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease, Iain B. McInnes, Bruce Kirkham, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 14, pp. 1329-1339
Open Access | Times Cited: 683
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 583
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten, Xenofon Baraliakos, J. Braun, et al.
The Lancet (2013) Vol. 382, Iss. 9906, pp. 1705-1713
Closed Access | Times Cited: 568
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 1, pp. 79-87
Open Access | Times Cited: 500
The pathogenesis of psoriatic arthritis
Douglas J. Veale, Ursula Fearon
The Lancet (2018) Vol. 391, Iss. 10136, pp. 2273-2284
Closed Access | Times Cited: 438
The IL-23–IL-17 axis in inflammatory arthritis
Erik Lubberts
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 7, pp. 415-429
Closed Access | Times Cited: 393
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer, Mélissa Noack, Pierre Miossec
Trends in Molecular Medicine (2016) Vol. 22, Iss. 3, pp. 230-241
Closed Access | Times Cited: 375
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, et al.
The Lancet (2017) Vol. 389, Iss. 10086, pp. 2317-2327
Closed Access | Times Cited: 353
Interleukin-17 and innate immunity in infections and chronic inflammation
Natasa Isailovic, Kenji Daigo, Alberto Mantovani, et al.
Journal of Autoimmunity (2015) Vol. 60, pp. 1-11
Closed Access | Times Cited: 346
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes, Joachim Sieper, J. Braun, et al.
Annals of the Rheumatic Diseases (2013) Vol. 73, Iss. 2, pp. 349-356
Open Access | Times Cited: 335
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, et al.
The Lancet (2018) Vol. 392, Iss. 10163, pp. 2441-2451
Open Access | Times Cited: 303
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
José María García Ruiz de Morales, L. Puig, E. Daudén, et al.
Autoimmunity Reviews (2019) Vol. 19, Iss. 1, pp. 102429-102429
Open Access | Times Cited: 271
Interleukin‐17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Bina Menon, Nicola Gullick, Gina Walter, et al.
Arthritis & Rheumatology (2014) Vol. 66, Iss. 5, pp. 1272-1281
Open Access | Times Cited: 258
Enrichment of circulating interleukin‐17–secreting interleukin‐23 receptor–positive γ/δ T cells in patients with active ankylosing spondylitis
Tony Kenna, Stuart I. Davidson, Ran Duan, et al.
Arthritis & Rheumatism (2011) Vol. 64, Iss. 5, pp. 1420-1429
Closed Access | Times Cited: 243
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
J. Braun, Xenofon Baraliakos, Atul Deodhar, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 6, pp. 1070-1077
Open Access | Times Cited: 241
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 241
Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
Bruce Kirkham, Arthur Kavanaugh, Kristian Reich
Immunology (2013) Vol. 141, Iss. 2, pp. 133-142
Open Access | Times Cited: 226
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
Daniele Mauro, Ranjeny Thomas, Giuliana Guggino, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 7, pp. 387-404
Closed Access | Times Cited: 225
β‐glucan triggers spondylarthritis and Crohn's disease–like ileitis in SKG mice
Merja Ruutu, Gethin Thomas, Roland Steck, et al.
Arthritis & Rheumatism (2012) Vol. 64, Iss. 7, pp. 2211-2222
Closed Access | Times Cited: 224
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu, Sheng Li, Shuni Ying, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 221
Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis
Judith A. Smith
Current Allergy and Asthma Reports (2014) Vol. 15, Iss. 1
Closed Access | Times Cited: 218
Review: The Interleukin‐23/Interleukin‐17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond
Judith A. Smith, Robert A. Colbert
Arthritis & Rheumatology (2013) Vol. 66, Iss. 2, pp. 231-241
Open Access | Times Cited: 213
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 206
Page 1 - Next Page

Scroll to top